The present study shows that long‐term treatment with tofogliflozin for 1 year was safe and clinically useful when administered to patients with type 2 diabetes mellitus receiving GLP‐1 receptor agonist monotherapy, whose HbA1c levels had been poorly controlled. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.